Integrated pharmacokinetic–Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets

BMC Veterinary Research

Research Article

Qing Lin Zeng¹  Jia Su¹  Xiao Hong Li¹  Xian Mei¹  Zhen Ling Zeng²  Wen Guang Xiong³  Yan Lu³ 

[1] National Laboratory of Safety Evaluation of veterinary Drugs, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China;National Laboratory of Safety Evaluation of veterinary Drugs, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China;National Laboratory of Safety Evaluation (Environmental Assessment) of Veterinary Drugs, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China;null;

关键词: Marbofloxacin;    PK/PD;    P. Multocida;    Tissue-cage model;    Piglets;   

DOI  :  10.1186/s12917-017-1099-z

 received in 2017-02-27, accepted in 2017-06-06,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundMarbofloxacin is a veterinary fluoroquinolone with high activity against Pasteurella multocida. We evaluated it’s in vivo activity against P. multocida based on in vivo time-kill data in swine using a tissue-cage model. A series of dosages ranging from 0.15 to 2.5 mg/kg were administered intramuscularly after challenge with P. multocida type B, serotype 2.ResultsThe ratio of the 24 h area under the concentration-time curve divided by the minimum inhibitory concentration (AUC24TCF/MIC) was the best PK/PD index correlated with the in vivo antibacterial effectiveness of marbofloxacin (R2 = 0.9279). The AUC24TCF/MIC necessary to achieve a 1-log10 CFU/ml reduction and a 3-log10 CFU/ml (90% of the maximum response) reduction as calculated by an inhibitory sigmoid Emax model were 13.48 h and 57.70 h, respectively.ConclusionsMarbofloxacin is adequate for the treatment of swine infected with P. multocida. The tissue-cage model played a significant role in achieving these PK/PD results.

【 授权许可】

CC BY   
© The Author(s). 2017